米氮平片联合帕罗西汀片治疗女性重度抑郁症的临床研究

发布时间：2018-07-04 22:29

本文选题：米氮平 + 帕罗西汀　；参考：《中国临床药理学杂志》2017年03期

【摘要】：目的观察米氮平片联合帕罗西汀片治疗女性重度抑郁症的临床疗效及安全性。方法将58例女性重度抑郁症患者随机分为对照组29例与试验组29例。对照组予以口服帕罗西汀初始剂量为20 mg qd,根据耐受情况调整剂量,最大剂量为50 mg qd;试验组在对照组治疗的基础上,予以口服米氮平起始剂量15mg qd,最大剂量为30 mg qd。2组患者均治疗6周。比较2组患者的临床疗效、5-羟色胺、多巴胺、去甲肾上腺素,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为82.76%(24/29例)和58.62%(17/29例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的5-羟色胺分别为(150.28±19.49),(124.29±15.59)pg·m L~(-1);多巴胺分别为(215.29±25.29),(248.39±29.29)μg·L~(-1);去甲肾上腺素(230.92±25.69),(255.39±26.77)pg·m L~(-1),差异均有统计学意义(P0.05)。试验组的药物不良反应主要有食欲缺乏、头晕、便秘、乏力和多汗,对照组的药物不良反应主要有镇静嗜睡、食欲缺乏、口干和谷丙转氨酶升高。试验组和对照组的药物不良反应发生率分别为20.69%和24.14%,差异无统计学意义(P0.05)。结论米氮平片联合帕罗西汀片治疗女性重度抑郁症的临床疗效显著,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the efficacy and safety of miazapine tablets combined with paroxetine tablets in the treatment of severe depression in women. Methods 58 female patients with severe depression were randomly divided into control group (n = 29) and trial group (n = 29). The initial dose of paroxetine was 20 mg QD in the control group, and the maximum dose was 50 mg QD according to tolerance. The initial dose of metozapine was 15mg QD, and the maximum dose was 30 mg qd.2 for 6 weeks. The clinical efficacy of 5-hydroxytryptamine, dopamine, norepinephrine and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 82.76% (24 / 29) and 58.62% (17 / 29), respectively. The difference was statistically significant (P0.05). After treatment, 5-hydroxytryptamine (150.28 卤19.49), (124.29 卤15.59) pg m L ~ (-1), dopamine (215.29 卤25.29), (248.39 卤29.29) 渭 g L ~ (-1) and norepinephrine (230.92 卤25.69), (255.39 卤26.77) pg m L ~ (-1) in the experimental group and control group were significantly different (P0.05). The main adverse drug reactions in the test group were appetite deficiency, dizziness, constipation, fatigue and sweating. In the control group, the main adverse drug reactions were sedation and lethargy, lack of appetite, dry mouth and elevated alanine aminotransferase. The incidence of adverse drug reactions in the experimental group and control group were 20.69% and 24.14% respectively, with no significant difference (P0.05). Conclusion the clinical efficacy of miazapine combined with paroxetine in the treatment of women with severe depression is significant, and the incidence of adverse drug reactions is not increased.
【作者单位】：连云港市第一人民医院药学部;连云港市第一人民医院神经内科;
【基金】：国家自然科学基金(青年科学基金)资助项目(81001427)
【分类号】：R749.4

【参考文献】